

A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women

Sung Won Lee MD, Margit Juhasz MD, Pezhman Mobasher MD, Chloe Ekelem MD,
and Natasha Atanaskova Mesinkovska MD PhD
University of California, Irvine, CA

ABSTRACT

Introduction: Currently, only topical minoxidil (MNX) and oral finasteride (FNS) are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of androgenetic alopecia. Although FNS is efficacious for hair regrowth, its systemic use is associated with side effects limiting long-term utilization. Exploring topical FNS as an alternative treatment regimen may prove promising.

Methods: A search was conducted to identify studies regarding human in vivo topical FNS treatment efficacy including clinically relevant case reports, randomized controlled trials (RCTs), and prospective studies.

Results: Seven articles were included in this systematic review. In all studies, there was significant decrease in the rate of hair loss, increase in total and terminal hair counts, and positive hair growth assessment with topical FNS. Both scalp and plasma DHT significantly decreased with application of topical FNS; no changes in serum testosterone were noted.

Conclusion: Preliminary results on the use of topical FNS are limited, but safe and promising. Continued research into drug-delivery, ideal topical concentration and application frequency, side effects, and use for other alopecias will help to elucidate the full extent of topical FNS' use.

J Drugs Dermatol. 2018;17(4):457-463.

INTRODUCTION

Androgenetic alopecia (AGA) is a common chronic, cutaneous condition encountered by dermatologists globally. AGA is androgen-dependent and characterized by a hereditary inheritance pattern, beginning with the advent of puberty. In predisposed males and females, scalp hair progressively thins in a defined pattern, most often at the vertex, with non-scarring, progressive miniaturization of the hair follicle and shaft.¹ Unfortunately, AGA is often accompanied by low self-esteem and negatively impacts quality of life. Despite its prevalence and patient morbidity, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA)-approved therapeutic options for AGA are limited to oral finasteride (FNS; Propecia®, Merck Pharmaceuticals, for men only) and topical minoxidil (MNX; Rogaine®, Johnson and Johnson Healthcare Products, for men and women).^{2,3} In the absence of other therapeutic modalities, practitioners may use surgical hair transplant; however, patients often encounter high cost because most insurance plans do not cover the procedure. In addition, transplants are associated with risks such as bleeding and infection.⁴

Pathogenesis of AGA is related to the purported binding of dihydrotestosterone (DHT) to androgen receptors (AR) located at the hair follicle. DHT is produced by conversion of testosterone using 5- α -reductase type 2, an enzyme located in the follicle dermal papilla. DHT levels are affected by factors including the abundance of weak androgens, testosterone conversion,

activity of androgen inactivating enzymes, and abundance of AR.^{5,6} AGA predisposed dermis exhibits high levels of DHT and increased expression of AR.⁷

Systemic FNS, a 5- α -reductase inhibitor 4-aza-3-oxosteroid compound, has been extensively studied and is clinically used for the treatment of benign prostate hyperplasia (BPH) and AGA.⁸ FNS works by competitively inhibiting 5- α -reductase type 2, preventing the conversion of testosterone to DHT, markedly suppressing serum DHT levels. The mean terminal half-life of FNS is approximately five to six hours in men 18-60 years, and eight hours in men greater than 70 years of age. DHT levels return to normal within 14 days of treatment discontinuation. It is expected that after systemic FNS use for the treatment of AGA is stopped, reversal of hair regrowth occurs within 12 months.³ In its systemic form, various side effects such as gynecomastia, breast tenderness, malignant neoplasms of the male breast, decreased ejaculate volume, decrease in testicular size, testicular pain, reduction in penile curvature, reduction in penile size, sexual disorder, male infertility, high grade prostate cancer, and prostatitis have been reported.³ These side effects are often prohibitive as male patients are sensitive to sexual side effects.

Animal studies have shown that topical FNS may have protective effects against AGA. Comparing topical FNS 2% solution to a fern

extract (*Adiantum capillus-veneris*) in a testosterone-induced alopecia albino mouse model demonstrates higher follicular density and anagen:telo-gen ratios in groups treated with topical FNS.⁹ In humans, topical FNS application for the treatment of AGA was first conducted twenty years ago by Mazarella et al in an attempt to analyze its efficacy and safety.¹⁰ In the past five years, emerging evidence suggests that topical FNS may be a promising treatment with a less severe side effect profile compared to systemic therapy. This review will provide a summary of past and current clinical studies investigating topical FNS therapy for AGA.

METHODS

A primary literature search was conducted using PubMed/MEDLINE, Embase, PsycINFO, TRIP Cochrane Library, and Cochrane Skin databases with search terms "[topical finasteride], [finasteride solution], [finasteride liquid], [finasteride foam], and [finasteride cream]". Given the focus of this article is the clinical application of topical FNS in humans, only studies regarding human in vivo topical FNS treatment efficacy were reviewed for inclusion; clinically relevant systematic reviews, randomized controlled trials, and open studies were

considered. Inclusion criteria were studies involving at least one treatment group with topical FNS, inclusion of results regarding efficacy of topical FNS, and the use of in vivo treatment only. Excluded studies included those that were not written in English, involved treatment with oral FNS only, and those that addressed only the mechanism or pharmacodynamics of the topical FNS. Included studies were graded using the Oxford Center for Evidence-Based Medicine 2011 Levels of Evidence.

RESULTS

119 articles were found using the methodology outlined above. Of these, 67 records were identified by title, and further narrowed to seven records after inclusion criteria were applied and duplicates were removed. Of the reviewed articles, six were published in the last eight years, while one was published 20 years ago, and include five RCTs and two prospective studies. Three studies compare topical to oral FNS, two compare topical MNX to a topical combination of MNX and FNS, one compares combination topical treatments containing FNS, and one compares varying doses and frequencies of topical FNS application. A total of 256 (24 female, 232 male) human subjects were studied (Figure 1, Table 1).

FIGURE 1. Selecting clinically relevant articles on the use of topical FNS in human subjects with AGA.




TABLE 1.

Summarizing the Results of Studies Demonstrating the Use of Topical FNS for the Treatment of AGA

Author	Level of Evidence	Sample Size	Study Design	Treatment(s)	Assessments	Study Outcome	Adverse Events
Mazarella et al (1997)	2	52 subjects total: 28 male, 24 female age range, 18-38 years	Randomized Controlled Trial (RCT)	Topical FNS 0.005% Solution vs. placebo for 16 months	Physician Assessments: Photograph 6-point hair regrowth scale "Wash test" Subject Assessments: Subjective 4-point scale of effectiveness (0 to 3, with 0 being no effect, and 3 being high effectiveness)	Significant decrease in rate of hair loss in FNS group after 6 months of treatment. Slight to marked reduction in balding areas in all FNS patients compared to baseline; placebo patients experienced no reduction. 73% of patients in FNS group reported moderate treatment effectiveness, 70% of the placebo group reported no to slight treatment effectiveness.	30% subjects withdrew from the placebo group due to treatment non-efficacy. No reported local or systemic effects in treatment or placebo groups.
Hajheydari et al (2009)	2	38 male subjects, mean age, 22.8 +/- 3 years	RCT	Topical FNS 1% gel with placebo oral tablet vs. oral FNS 1 mg with placebo gel for 6 months	Size of bald area Total hair count Terminal hair count	Statistically significant increase in total and terminal hair count compared to baseline in both groups after 4 months. Significant size decrease of bald area compared to baseline in oral FNS group can be seen earlier when compared to the topical FNS group. No significant difference between the two groups in hair thickness, total hair counts and the size of bald area.	Erythema of scalp after application of topical FNS (n=1). Decreased libido with use of systemic FNS (n= 1).
Rafi and Katz (2011)	3	15 male subjects, age range, 24-72 years	Prospective cohort	NuH Hair (topical FNS, dutasteride, MNX) with the option to add oral FNS, topical MNX, and/or ketoconazole shampoo for 9 months (NuH Hair) formulation is currently a trade secret. The overall contents, composition percentages, and formulation methods are not revealed.	Photographs	All patients demonstrated significant growth of hair compared to baseline. In those patients who utilized all 4 components, significant growth compared to baseline was achieved in as little as 30 days. In those patients who chose to apply NuH Hair only, significant growth compared to baseline was demonstrated after 3 months.	No report of contact or irritant dermatitis were reported with the use of NuH Hair.
Tanglertsampan (2012)	2	33 male subjects, age range, 27-49 years	RCT	Topical MNX 3% alone vs. MNX 3% + FNS 0.1% (MFX) lotion for 24 weeks	Hair count Photographs	Hair count increased in both groups, but was only significantly improved from baseline in the MFX group. MFX showed significantly higher efficacy by global photographic assessment compared to MNX.	Contact dermatitis experienced in MNX group n=6 (38%), MFX group n=4 (24%).
Caserini et al (2014)	2	23 male subjects, age range, 18-65 years	RCT	Topical FNS 0.25% solution twice daily vs. oral FNS 1 mg once daily for 7 days	DHT and testosterone levels in plasma	Plasma DHT was reduced by 68-75% with use of topical FNS and by 62-72% with systemic administration. No relevant changes occurred for plasma testosterone with either treatment.	No clinically significant adverse events occurred.

TABLE 1. Continued

Summarizing the Results of Studies Demonstrating the Use of Topical FNS for the Treatment of AGA

Author	Level of Evidence	Sample Size	Study Design	Treatment(s)	Assessments	Study Outcome	Adverse Events
Caserini et al (2016)	2	50 male subjects, age range, 18-65 years	RCT	<p>Study 1: 1 mL (2.275 mg) topical FNS solution 0.25% daily vs. 1 mL topical FNS 0.25% twice daily vs. oral FNS 1 mg daily for 7 days</p> <p>Study 2: Placebo vs topical FNS 0.25% daily in varying quantities 100 µl (0.2275 mg) vs. 200 µl (0.455 mg) vs. 300 µl (0.6825 mg) vs. 400 µl (0.91 mg) for 7 days</p>	<p>DHT Concentration in scalp and plasma</p> <p>Testosterone levels in plasma</p> <p>FNS levels in plasma</p>	<p>Study 1: 70% decrease from baseline in scalp DHT after application of 1 mL topical FNS daily compared to 50% decrease from baseline for both 1 mL topical FNS twice daily or oral FNS.</p> <p>Study 2: Scalp DHT reduction was decreased by 47 and 52% using 100 µl and 200 µl topical FNS, respectively, which was similar to that of 37% and 54% reduction seen with 300 µl and 400 µl, respectively.</p> <p>Serum DHT was reduced by 24%, 26%, 44%, and 48% by 100 µl, 200 µl, 300 µl, and 400 µl, respectively. No significant changed occurred in serum testosterone levels.</p>	<p>Study 1: Increased alanine aminotransferase, pollakiuria and testicular pain (n=2, 11.1%)</p> <p>Study 2: Presyncope, conjunctivitis, headache, oropharyngeal pain (n=5, 15.6%)</p>
Chandrashekar et al (2017)	3	50 male subjects, age range, 20-40 years	Retrospective assessment and Prospective cross-over cohort	<p>Topical MNX 5% and oral FNS 1 mg for 2 years, followed by either topical MNX 5% fortified with FNS 0.1% for 1 year either immediately or after 8-12 months without treatment</p> <p>(The study does not mention about the type of topical application form)</p>	Photographs	<p>45 subjects underwent continuous treatment with MNX and oral FNS for 2 years and then treatment was continued with MNX 5% + FNS 0.1%.</p> <p>Of these patients, 84.4% maintained good hair density while on MFX.</p> <p>5 subjects underwent continuous treatment with MNX and oral FNS for 2 years, were discontinued from all treatments for 8-12 months, and then treatment was continued with MNX 5% + FNS 0.1%.</p> <p>Of these patients, 80% maintained good hair density while on MNX 5% + FNS 0.1%.</p>	<p>No adverse events were reported with either treatment.</p> <p>Patient compliance was good with topical FNS.</p>

Assessing Systemic Pharmacodynamics of Topical Finasteride

The first study on topical finasteride in humans was completed in 1997 by Mazarella et al as a single-blind, placebo-controlled study, including 28 males and 24 females patients with AGA. Subjects were randomized to receive either 1.0 mL topical FNS 0.005% solution or placebo twice daily to the affected scalp for 16 months. Pharmacodynamic data reveals no significant change in plasma levels of total testosterone, free testosterone, and DHT between the groups. At sixth months, researchers observed a significant decrease in the rate of hair loss in the topical FNS compared to the placebo group. Patients' opinion on the effectiveness of treatment was generally positive among the FNS group, with 73% of treated patients reporting "high effectiveness", compared to 60% of placebo patients reporting "no effect".¹⁰

Five years later, a double-blind, randomized clinical trial with 45 AGA male patients compared topical FNS gel 1% to the scalp twice daily with oral placebo tablets (group A) to oral FNS 1 mg daily with a control vehicle (group B) applied to the scalp twice daily. In group A, increased terminal hair counts were observed at the third month of treatment ($P=0.001$); however, increased hair counts were noted one month earlier in the group B (FNS tablet and placebo gel). During therapeutic period, the size of alopecia area(s) was not significantly altered in group A, but in group B the change in alopecia area was significant at the fourth month of treatment. Both groups demonstrated increased hair counts with moderate therapeutic response but no differences were noted between treatment groups.¹¹

Studies comparing topical FNS 0.25% (2.275 mg/mL) (P-3074) to systemic FNS 1 mg tablets for AGA therapy have shown

that both therapies significantly suppress plasma DHT levels. Caserini et al randomized 24 male patients in a single-center, open-label, parallel-group, exploratory study with subjects either applying topical solution to their shaved scalp twice daily, or taking a tablet once daily for seven days. Although there is decreased absorption of topical FNS compared to oral, the authors note a decrease in plasma DHT levels after one week of treatment with either topical or oral formulations. This study provides the first evidence that topical FNS slows AGA-associated hair loss by modulating DHT levels, while also reducing systemic exposure to the medication.¹²

A follow-up study also by Caserini et al further examined the dose-dependent effects of topical FNS using a randomized, parallel-group design. The first part of this study examined 18 male patients applying 1 mL of topical FNS 0.25% solution to the scalp once or twice daily, versus administration of oral FNS 1 mg tablet once daily for seven days. There were an increase in alanine aminotransferase, pollakiuria, and testicular pain reported in two participants. In the second part, a group of 32 men received either placebo, or 100 µL (0.2275mg), 200 µL (0.455 mg), 300 µL (0.6285 mg) or 400 µL (0.91 mg) topical FNS 0.25% solution to apply to the scalp once daily for seven days. Interestingly, the results suggest that once daily application of topical FNS is more efficacious at decreasing scalp and plasma DHT levels than twice daily application, and is non-inferior to oral FNS administration. There were no significant differences between the varying concentrations of topical FNS, however the 300 and 400 µL doses are associated with higher plasma concentrations of FNS, and therefore at greater risk for systemic side effects. Presyncope, conjunctivitis, headache, and oropharyngeal pain were rarely reported. The authors concluded that the 100 and 200 µL doses of topical FNS applied daily may be the most effective treatment regimen for AGA.¹³

Combining Topical Finasteride With Other Agents

Research has also been completed to demonstrate the efficacy of topical FNS for AGA in comparison to topical combination therapies. A novel combination topical treatment by the name NuH Hair [topical FNS, dutasteride and minoxidil (MNX)], was formulated by Rafi and Katz. 15 male patients were asked to apply the solution daily for nine months and were given the option of adding three further components to their treatment protocol: 1) oral FNS 1 mg daily 2) topical MNX 5% foam applied at least once per day, and/or 3) topical ketoconazole 2% shampoo applied 2-3 times per week. Eight subjects chose aggressive treatment with all four treatment modalities simultaneously. While all 15 patients demonstrated significant growth of hair by the end of the treatment period, the eight patients who utilized all four treatment options experienced significant growth in as little as 30 days; for the patients using topical FNS/dutasteride/MNX alone, significant hair growth was experienced after three months. The topical FNS/dutasteride/MNX was formulated as

a hypoallergenic lotion and found to be safe even in subjects with atopy.¹⁴

A randomized, double-blind, comparative study assessed the efficacy and safety of twice daily topical MNX 3% versus topical combined MNX 3%/FNS 0.1% in 40 men with AGA for 24 weeks. Both groups demonstrated increased hair counts from baseline with the MNX 3%/FNS 0.1% group showed statically superior improvement compared to the MNX group.¹⁵ Further studies with retrospective assessment and prospective cohort tested a higher concentration of topical MNX 5%/FNS 0.1% for one year in 50 men with AGA who were previously treated with oral FNS 1 mg daily and topical MNX 5% twice a day for two years. Approximately 80% of patients either maintained or improved their baseline hair density using topical combination therapy.¹⁶

DISCUSSION

Topical application of FNS in the treatment of AGA is an area of research in its infancy and limited to a small number of randomized-controlled trials, prospective studies, and retrospective medical record review. Overall data from the studies on investigating the efficacy and safety of topical FNS in AGA show promising results and non-inferiority compared to systemic delivery.

Although preliminary results on the use of topical FNS are limited, the studies reviewed demonstrate that topical FNS may be safe for use in patients wishing to avoid systemic side effects. This may be especially important for the female AGA population, in which systemic FNS is not approved due to hormonal suppression and is considered a category X drug during pregnancy.³ It is possible that topical FNS will follow the same path as topical retinoid derivatives (category C)¹⁷ and their parent systemic drug isotretinoin (category X),¹⁸ with the topical formulation of FNS considered relatively safe for use in pregnant females if the benefits outweigh the risk.

With consistent inhibitory effects on scalp DHT levels while minimizing the systemic effects on serum DHT, doses of 100 µL (0.2275mg) and 200 µL (0.455 mg) topical FNS 0.25% solution applied daily appears to be the most efficacious concentration and frequency at this time.¹³ The use of topical FNS has not resulted in the report of serious side effects; however, there are reports of scalp irritation manifesting as erythema and contact dermatitis, as well as cases of increased liver enzymes, bed-wetting, testicular pain, headaches, presyncope, and oropharyngeal pain (Table 1).^{11,13,15} Although current evidence suggests that patients are satisfied and that the drug is well-tolerated, we believe large cohort studies examining the potential adverse effect profile of the drug are warranted.

Several challenges arise from the available studies on topical FNS including the vehicle, concentration, as well as application

regimen and frequency. The delivery of topical pharmacologic drug to any dermatologic disease state is a heavily studied and debated subject; pharmacokinetic and -dynamic properties, solubility, concentration, potency, drug-drug interactions, absorption, and degradation are dependent on the exact formulation of the vehicle. For the treatment of AGA, the variable efficacy of topical FNS formulations likely depends on the composition of the vehicle.¹⁹ Currently, topical formulations of FNS have been tested as gels and solutions at varying concentrations, all of which have resulted in improved hair growth.¹⁰⁻¹⁶

There is no study comparing vehicle delivery (gel versus solution), and it is unknown which formulation is the most effective at penetrating the scalp, stabilizing FNS over a period of time (ie, prolonging shelf-life), delivering drug, and producing hair regrowth. Combining topical FNS with MNX and/or dutasteride has shown greater efficacy at hair regrowth than topical MNX alone,¹⁴ and also allowed for the maintenance of hair density. Researchers have optimized the penetration of FNS into the dermis by modulating the type and size of particles transporting the medication across the skin. Studies evaluating the efficacy of nanoparticle delivery have shown enhanced absorption of FNS with smaller particles, particularly in the liquid crystalline variation.^{20,21} Liposomes and microplated films are also successful delivery methods, as well as the use of absorption enhancers, such as ethanol and propylene glycol.^{22,23,24} A head-to-head comparison of compounds used to deliver nanoparticles has yet to be done, and no conclusions can be drawn at this time regarding which formulation will be most efficacious, with the least amount of adverse events, and the most cost-effective. Although most studies apply topical solution twice daily, once daily application of topical FNS is more effective at decreasing scalp DHT levels.¹³ Other studies reveal that combination of topical medications such as MNX 5% with FNS 0.1% may have synergistic and additive effects compared to single agent usage.^{14,15,16}

In the future, further research clarifying an optimal drug-delivery system, ideal concentration and frequency of the drug application, the adverse effect profile, as well as use in other hair loss disorders is required to determine the full extent to which topical FNS may be used.

CONCLUSION

AGA is a debilitating chronic condition, causing a great deal of psychological patient morbidity and decreased patient quality of life. Preliminary results regarding the application of topical FNS for the treatment of AGA are promising. Current data suggests that there may be a therapeutic potential for topical FNS in the treatment of AGA, while minimizing unwanted systemic side effects associated with oral use. Topical FNS appears to be non-inferior for hair regrowth when compared to systemic FNS. Combination therapies including topical FNS, as

well as MNX or dutasteride, may be more effective than topical FNS alone. Topical FNS is not widely used despite its proven efficacy and lack of side effects, most likely due to the lack of evidence-based research. At this time it is unknown whether the cost of compounding topical FNS is a barrier to treatment. Given the benefits of topical FNS in both male and female AGA patients, further studies are warranted to determine the efficacy of long-term hair regrowth, therapeutic safety, cost-effectiveness, patient tolerability, and satisfaction.

DISCLOSURES

The authors have no conflicts of interest to disclose and have received no financial support for this research.

REFERENCES

- Lolli F, Pallotti F, Rossi A, Fortuna MC, et al. Androgenetic alopecia: a review. *Endocrine*. 2017;57(1):9-17.
- U.S. Food & Drug Administration: Drug Databases. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021812s000TOC.cfm. Accessed July 07, 2017.
- U.S. Food & Drug Administration: Drug Databases. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020788s018lbl.pdf. Accessed July 07, 2017.
- Robinson J. Hair transplants: what to expect. WebMD. <https://www.webmd.com/skin-problems-and-treatments/hair-loss/men-hair-loss-17/hair-transplants>. Published December 18, 2016. Accessed July 04, 2017.
- Inui S, Itami S. Androgen actions on the human hair follicle: perspectives. *Exp Dermatol*. 2012.
- El-Domyati M, Attia S, Saleh F, et al. Androgenetic alopecia in males: a histopathological and ultrastructural study. *J Cosmet Dermatol*. 2009;8(2):83-91.
- Trueb RM. Molecular mechanisms of androgenetic alopecia. *Ther Umsch*. 2002;59(5):211-6.
- Finn DA, Beadles-Bohling AS, Beckley EH, et al. A new look at the 5 α -reductase inhibitor finasteride. *Cns Drug Rev*. 2006;12:53-76.
- Noubarani M, Rostamkhani H, Erfan M, Kamalinejad M, Eskandari MR, Babaeian M, Salamzadeh J. Effect of adiantum capillus veneris linn on an animal model of testosterone-induced hair loss. *Iran J Pharm Res*. 2014;13(Suppl):113-118.
- Mazzarella GF, Loconsole GF, Cammisia GA, Mastrodonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. *J of Derm Tr*. 1997;8(3):189-92.
- Hajheydari Z, Akbari J, Saeedi M, Shokooi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. *Exp Gerontol*. 2002;37(9-10):981-90.
- Caserini M 1, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. *Int J Clin Pharmacol Ther*. 2014;52(10):842-9.
- Caserini M 2, Radicioni M, Leuratti C, et al. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. *Int J Clin Pharmacol Ther*. 2016;54(1):19-27.
- Rafi AW, Katz RM. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. *ISRN Dermatol*. 2011;2011:241953. Published online.
- Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. *J Med Assoc Thai*. 2012;95(10):1312-6.
- Chandrashekar BS, Nandhini T, Sriram R, Navale S. Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. *Indian Dermatol Online J*. 2015;6(1):17-20.
- U.S. Food & Drug Administration: Drug Databases. <https://www.fda.gov/ohrms/dockets/dockets/05p0417/05p0417-sup0001-03-Retin-A-Labeling-vol2.pdf>. Accessed October 04, 2017.
- U.S. Food & Drug Administration: Drug Databases. https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/18662s051lbl.pdf. Accessed July 04, 2017.
- Sintov A, Serafimovich S, Gilhar A. New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice. *Int J of Pharmaceutics*. 2000;194:125-134.
- Roque LV, Dias IS, Cruz N, Rebelo A, Robert A, Rijo P, Reis CP. Design of Finasteride-loaded nanoparticles for potential treatment of alopecia. *Skin Pharmacol Physiol*. 2017;30:197-204.

21. Gomes MJ, Martins S, Ferreira D, Segundo M, Reis S. Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physiochemical characterization, and in vitro release and penetration studies. *Skin Pharmacol Physiol*. 2017;30(4):197-204.
22. Kumar R, Singh B, Bakshi G, Katore OP. Development of liposomal systems of finasteride for topical applications: designs, characterization, and in vitro evaluation. *Pharm Dev Technol*. 2007;12(6):591-601.
23. Ahmed TA, El-Say KM. Transdermal film-loaded finasteride microplates to enhance drug skin permeation: two-step optimization study. *Eur J Pharm Sci*. 2016;88:246-56.
24. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. *Int. J Pharm* 2006;323(1-2):1-10.

AUTHOR CORRESPONDENCE

Natasha Atanaskova Mesinkovska MD PhD

E-mail:..... nmesinko@uci.edu